ADAGIO THERAPEUTICS INC (ADGI)
US00534A1025 - Common Stock
Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants
Integrated discovery platform is producing a stream of candidate antibodies demonstrating broad in vitro neutralization against past variants of concern...
Adagio Therapeutics Announces Corporate Name Change to Invivyd
New name reflects Company focus on leveraging its integrated discovery platform to generate anti-viral antibodies that transcend the limits of naturally...
Adagio Therapeutics to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the...
Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
$475 Million in Cash and Cash Equivalents to Support Operating Runway into Second Quarter of 2024 Integrated Discovery Platform Identifies Multiple New...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, investor! Wednesday starts with a breakdown of the biggest pre-market stock movers for traders to keep an eye on!
Mithril Capital’s Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for Support of Successful Proxy Campaign
Adagio Announces David Hering Named Permanent Chief Executive Officer and Director
WALTHAM, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the...
Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors
Marc Elia Named Chair of the Board of Directors...
Adagio Therapeutics Reports First Quarter 2022 Financial Results
$532.2 Million in Total Cash at Quarter End; Strong Balance Sheet Expected to Support Operations into Second Half of 2024 Additional Data from...
Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request
WALTHAM, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the...
Adagio Therapeutics 宣佈 ADG20（adintrevimab）是第一個滿足主要終點的單克隆抗體，在接觸 2019 冠狀病毒病前後的預防和治療中具有統計學意義，並計劃尋求美國緊急使用授權
與安慰劑相比，在接觸前預防出現 2019 冠狀病毒病症狀的風險降低了 71%，在接觸後預防中降低了 75% 在主要療效分析人群中，與安慰劑相比，患有輕度至中度 2019 冠狀病毒病的參與者的住院或死亡風險降低了 66%，在症狀出現三天內接受治療的參與者中，與安慰劑相比降低了 77% 報告 2021...
Adagio Therapeutics annonce que l'ADG20 (adintrevimab) est le premier anticorps monoclonal à répondre aux critères d'évaluation primaires ayant une importance statistique dans l'ensemble de la prophylaxie pré et post-exposition et du traitement pour la
Le risque de COVID-19 symptomatique a été réduit de 71 % par rapport au placebo dans la prophylaxie pré-exposition et de 75 % par rapport au placebo dans...
Adagio Therapeutics gibt bekannt, dass ADG20 (Adintrevimab) der erste monoklonale Antikörper ist, der die primären Endpunkte der Prophylaxe vor und nach Exposition sowie der Behandlung von COVID-19 mit statistischer Signifikanz erreicht hat, und plant die
Das Risiko einer symptomatischen COVID-19-Erkrankung wurde bei der Prophylaxe vor Exposition um 71 % und bei der Prophylaxe nach Exposition um 75 % im...
アダジオ・セラピューティクス（Adagio Therapeutics）、ADG20（Adintrevimab）が新型コロナウイルスの暴露前後の予防と治療において統計的に有意な主要エンドポイントを満たす最初のモノクローナル抗体であり、米国の緊急使用許可を求める予定であると発表
症候性新型コロナウイルスのリスクは、プラセボと比較して、暴露前予防では71％減少、暴露後予防では75％減少 軽度から中等度の新型コロナウイルス暴露者の入院または死亡のリスクは、一次有効性分析集団のプラセボと比較して66％減少、症状発現から3日以内に治療を受けた参加者のプラセボと比較して77％減少 ...
Adagio Therapeutics의 ADG20(adintrevimab), 1차 평가변수 충족한 최초의 단일 클론 항체로 코로나19 노출 전후 예방 및 치료에 있어 통계학적으로 유의미한 결과 보이며 미국에서 긴급사용승인 추진
유증상 코로나19의 노출 전 감염 위험, 위약 대비 71% 감소, 노출 후 감염 위험은 75% 감소 1차 효능 분석 결과 경증 코로나19 환자의 입원 및 사망 위험, 위약 대비 66% 감소, 증상 발현 후 3일 이내 치료한 환자의 경우 위약 집단 대비 위험이 77% 감소 ...
Adagio Therapeutics Mengumumkan ADG20 (adintrevimab) adalah Antibodi Monoklonal Pertama untuk Memenuhi Titik Akhir Utama dengan Kepentingan Statistik Merentas Profilaksis dan Rawatan Pra dan Pos Pendedahan untuk COVID-19 dan Merancang untuk Mendapatkan
Risiko COVID-19 bergejala telah dikurangkan sebanyak 71% berbanding plasebo dalam profilaksis pra-pendedahan dan 75% berbanding plasebo dalam profilaksis...
Adagio Therapeutics anuncia que o ADG20 (adintrevimabe) é o primeiro anticorpo monoclonal a atingir a meta final principal com significância estatística na profilaxia e tratamento pré e pós-exposição à COVID-19, e que pretende solicitar autorização de uso
O risco de COVID-19 sintomático foi reduzido em 71% em comparação com placebo na profilaxia pré-exposição e 75% em comparação com placebo na profilaxia...
Adagio Therapeutics anuncia que ADG20 (adintrevimab) es el primer anticuerpo monoclonal que cumple con los principales criterios de valoración con importancia estadística en la profilaxis pre-exposición (PrEP) y profilaxis post-exposición (PEP).y
El riesgo de COVID-19 sintomático fue reducido en un 71% en comparación con placebo en la profilaxis pre-exposición y 75% en comparación con placebo en la...
The Petri Dish: Adagio says its antibody works against omicron now
Noteworthy Wednesday Option Activity: ADGI, KALU, DIS
Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?
Penny stocks are a hot subject today with several of the top companies in the market seeing major gains on Wednesday and we know why!